Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody*

Received for publication, April 13, 2015, and in revised form, August 5, 2015. Published, JBC Papers in Press, August 10, 2015, DOI 10.1074/jbc.M115.651653

Stephen W. Jarantow‡, Barbara S. Bushey‡, Jose R. Pardinas‡, Ken Boakye‡, Eilyn R. Lacy‡, Renouard Sanders§, Manuel A. Sepulveda‡, Sheri L. Moores‡, and Mark L. Chiu*†

From ‡Janssen Research and Development, LLC, Spring House, Pennsylvania 19477 and §Janssen Diagnostics, Janssen Research and Development, Huntington Valley, Pennsylvania 19104

**Author’s Choice—Final version free via Creative Commons CC-BY license.

Background: Cancer cells express surface antigens at different levels from normal cells.

Results: Differences in EGFR and c-MET receptor density levels influenced the in vitro activity of an EGFR × c-MET bispecific antibody.

Conclusion: Consideration of target expression levels is important for bsAb design.

Significance: In addition to multiple pathway targeting, the unique avidity of bsAbs contributes to their promise for cancer therapy.

The efficacy of engaging multiple drug targets using bsAbs is affected by the relative cell-surface protein levels of the respective targets. In this work, the receptor density values were correlated to the in vitro activity of a BsAb (JNJ-61186372) targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET). Simultaneous binding of the BsAb to both receptors was confirmed in vitro. By using controlled Fab-arm exchange, a set of BsAbs targeting EGFR and c-MET was generated to establish an accurate receptor quantitation of a panel of lung and gastric cancer cell lines expressing heterogeneous levels of EGFR and c-MET. EGFR and c-MET receptor density levels were correlated to the respective gene expression levels as well as to the respective receptor phosphorylation inhibition values. We observed a bias in BsAb binding toward the more highly expressed of the two receptors, EGFR or c-MET, which resulted in the enhanced in vitro potency of JNJ-61186372 against the less highly expressed target. On the basis of these observations, we propose an avidity model of how JNJ-61186372 engages EGFR and c-MET with potentially broad implications for bsAb drug efficacy and design.

The modulation of a signaling pathway by a therapeutic monoclonal antibody (mAb) requires reaching a threshold of target engagement to achieve efficacy. This threshold is partially determined by the affinity and avidity of the mAb for its target (1, 2). Thus, target antigen density can play a prominent role in guiding mAb behavior (2). In vitro models where antigen density can be systematically controlled and dependent biological responses evaluated have been reported (3). However, they are difficult to generate in therapeutically relevant cellular backgrounds that are based on tumor models. It has been shown that differences in antibody-dependent cellular cytotoxicity measured against certain cancer targets (e.g. CD20) suggest the existence of a minimum expression level below which activity cannot be achieved (4–7). Beers et al. (8) demonstrated that in vitro effector functions such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity can be modified by treatment-induced changes in target expression levels.

Malignant cells frequently have altered cell-surface protein expression compared with normal cells (9–11). These expression differences have broad implications for target selection, tissue penetration, drug specificity, and efficacy, and in a clinical setting they have broad implications for the effects of diagnosis, disease monitoring, and treatment modulation (1, 11–13). A number of recent reviews highlight the potential importance of intratumoral heterogeneity, likely intrinsic to many cancer types, as a source of resistance to currently available therapies (14–16). In the case of non-small cell lung cancers (NSCLC),2 mutational heterogeneity in epidermal growth factor (EGF) receptor (EGFR) provides one possible escape mechanism for patients exhibiting resistance to tyrosine kinase inhibitors (14, 15, 17, 18). Activation of the hepatocyte growth factor receptor (c-MET, mesenchymal endothelial transition) pathway, which like EGFR can drive cellular proliferation, provides another major route of resistance (19, 20). The simultaneous targeting of both signaling pathways with an EGFR x c-MET bsAb could produce synergies that

The abbreviations used are: NSCLC, non-small cell lung cancer; Ab, antibody; ABC, antibody binding capacity; B2M, β2 microglobulin; BsAb, bsAb, bispecific antibody; cFAE, controlled Fab-arm exchange; HGF, hepatocyte growth factor; MFI, mean fluorescence intensity; 4PL, four parameter logistic; EGFR, epidermal growth factor receptor; QFCM, quantitative flow cytometry; R-PE, (R)-phyceroerythrin; SEC, size-exclusion chromatography; NEAA, nonessential amino acid; EFC, enzyme fragment complementation; SPR, surface plasmon resonance; F/P, fluorochrome to protein; CV, column volume; S/N, signal to noise ratio.

* The authors declare that they have no conflicts of interest with the contents of this article.

© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
Relative Antigen Levels Affect Bispecific Antibody Behavior

TABLE 1

Genotypes of EGFR and c-MET in cancer cell lines

The following abbreviations were used: ACA, adenocarcinoma; del, deletion mutant; BAC, bronchioalveolar carcinoma; MEC, mucoepidermoid carcinoma; ND, not determined; SCC, squamous cell carcinoma; UNK, unknown, WT, wild type; Y, yes; N, no.

| Cell line | Origin | EGFR Genotype | Amplified copies/cell | c-MET Genotype | Amplified copies/cell |
|-----------|--------|---------------|-----------------------|----------------|-----------------------|
| H292      | Lung MEC | WT            | N                     | WT             | N                     |
| SKMES-1   | Lung SCC | WT            | N                     | WT             | N                     |
| HCC827    | Lung ACA | del (E746, A750) | Y (19)               | WT             | N                     |
| H1975     | Lung ACA | L858R, T790M  | N                     | WT             | N                     |
| H5255     | Lung ACA | L858R         | Y (12)                | WT             | N                     |
| H1650     | Lung BAC | del (E746, A750) | Y (4)               | WT             | N                     |
| HCC4006   | Lung ACA | del (L747, S752) | Y (5)               | WT             | N                     |
| HCC2935   | Lung ACA | del (E746, A750) | N                     | WT             | N                     |
| H820a     | Lung ACA | del (E746, A750), T790M | UNK*              | WT             | Y (4–6)               |
| H1993*    | Lung ACA | WT            | UNK*                  | WT             | Y (UNK*)             |
| SNU-5     | Stomach ACA | WT         | N                     | WT             | Y (9)                 |

* Not in Cancer Cell Line Encyclopedia.

more effectively block tumor proliferation and metastasis (21–23).

An assessment of the therapeutic value of a BsAb entails a comparison of binding and functional activity of the BsAb with that of the individual parental mAbs that comprise it. The role that the surface density of each target plays in determining the efficacy of a BsAb, particularly in the context of heterogeneous cancer cell populations, remains to be thoroughly explored. We are interested in how JNJ-61186372 engages EGFR and c-MET on the cell surface and how the relative expression of its two targets influences its behavior. Starting with well established methods for receptor quantitation using flow cytometry, we have applied an improved set of tools made available by controlled Fab-arm exchange (cFAE) technology (24) to explore whether expression data correlate to receptor density and whether in vitro differences in activity might arise from differences in the relative expression of EGFR and c-MET.

We determined the cell-surface density of EGFR and c-MET in a panel of cancer cell lines grown under uniform conditions using flow cytometry. The application of flow cytometry methods to the quantitation of cell-surface antigens has become widespread since its introduction in the 1980s (13, 25). The term quantitative flow cytometry (QFCM) was coined to describe a set of methodologies for quantitation designed to standardize procedures and reagents to minimize inter-laboratory variability (11). In contrast to older qualitative methods, the assignment of defined values to describe antigen densities has demonstrated value in a wide range of applications (26). Notable studies using QFCM include the evaluation of differences in lymphocyte antigen expression in HIV (27–29), the characterization of malignancy, and the identification of prognostic indicators in leukemia (27, 30–32). QFCM has also been applied to the determination of genetic heterozygosity, the diagnosis of sepsis, and the study of multidrug resistance (11, 34). Nonetheless, the inherent challenges associated with QFCM have left standardization a lingering challenge for the scientific community (25, 35).

Although determining the number of epitopes per cell for a given antigen is typically the goal of QFCM, quantitative data are routinely generated with monoclonal Abs conjugated to a fluorochrome and are reported as the antibody-binding capacity (ABC) (36). However, the bivalency of monoclonal Abs obscures the precise determination of epitope number. Although investigation of the valency of Ab binding could potentially improve the accuracy of density measurements, these studies are typically not performed due to their laborious nature (37, 38). The advent of cFAE technology to generate bispecific Abs creates a novel and convenient opportunity for quantifying surface antigens. The combination of one antigen-specific Fab arm, and a binding arm that binds to an inert antigen that is not present on the target cell, enables researchers to construct full-length monovalent Abs. The use of monovalent Abs for quantitation removes inaccuracies introduced by the valency of binding when using conventional monoclonal Abs and removes the need to design and prepare constructs of different sizes (e.g. Fab and scFv) to achieve monovalency. Using different architectures of binders can affect the nature of interactions and thereby make systematic comparisons difficult to achieve. Because monovalent Abs lack avidity, the use of high affinity antigen-specific variants is essential (39). Equally important to our method is the application of labeling and purification methodologies that result in a 1:1 fluorochrome to protein (F/P) molar labeling ratio. The latter obviates the need to account for multiple and/or heterogeneous labeling ratios when interpreting fluorescent data. Although not the primary focus of this investigation, the ability to compare a monovalent full-length Ab to its bivalent parental Ab also makes possible a thorough investigation of the stoichiometry of binding.

In this paper, we demonstrate how BsAbs against EGFR and c-MET generated using cFAE can be used for accurate receptor quantitation, as well as to gain insight into the mechanisms of bispecific target engagement and their biological consequences in a cellular context. An approach to characterization of dual target engagement is also presented for an array of lung and gastric cancer cell lines that reflect diversity in the mutational status of EGFR and c-MET (Table 1). We also demonstrate the simultaneous binding of JNJ-61186372 to both the EGFR and c-MET via SPR and cell-based assays.

Experimental Procedures

Cell Culture—The 11 tumor cell lines included H292, SKMES-1, HCC827, H1975, H3255, H1650, HCC4006, HCC2935, H820, H1993, and SNU-5. The tumor cell lines were obtained from the American Type Culture Collection (ATCC,
Buffer B (50 mM citrate, pH 3.5). The eluate was buffer-exchanged with 10 CVs of Buffer A to remove any noncovalently bound material. Protein concentration was determined by absorbance at 280 and 310 nm. Quality was assessed by high performance size-exclusion chromatography (SEC) and SDS-PAGE of reduced and nonreduced samples.

cFAE to Generate BsAbs—Human IgG1 BsAbs were produced from the two purified bivalent parental Abs according to Labrijn et al. (24). Briefly, each parental Ab had been modified to carry a single complementary matched mutation in its third constant domain (CH3), K409R and F405L. The two parental Abs, IgG1-F405L and IgG1-K409R, were mixed in equimolar amounts and allowed to undergo recombination at 31 °C for 5 h in the presence of 75 mM of the mild reducing agent 2-mercaptoethanol-HCl (Sigma). The 2-mercaptoethanol-HCl was removed by three rounds of PBS dialysis using a Slide-A-Lyzer cassette (Thermo Scientific) as per the manufacturer’s instructions. The dialyzed solution was passed through a low protein-binding 0.2-µm syringe filter (Pall Corp.) in a laminar flow cabinet. BsAb quality was assessed by SDS-PAGE, high performance-SEC and cation-exchange liquid chromatography. BsAb yields were typically > 95%.

Binding of EGFR and c-MET via SPR—To determine binding of c-MET and EGFR arms of JNJ-61186372, a ProteOn experiment was performed by having recombinant human c-MET-Fc-His (R&D Systems, catalog no. 1095-ER) first captured onto an HTG sensor chip (Bio-Rad catalog no. 176-5031). After the anti-EGFR/c-MET mAbs or JNJ-61186372 was injected, the sensorgrams were fitted using a 1:1 binding model to determine kinetics and affinity. The experiments to determine affinity for EGFR were conducted by first capturing JNJ-61186372 with an anti-Human Fcγ-specific Ab (Jackson ImmunoResearch) covalently immobilized on a GLC sensor chip (Bio-Rad catalog no. 176-5011) using amine coupling chemistry, according to the manufacturer’s instructions. Subsequently, different concentrations of analyte, the monomeric extracellular domain (ECD) of EGFR (R&D Systems, catalog no. 1095-ER), were injected over the chip surface. Capture surface regeneration was performed using 10 mM glycine, pH 1.5.

Co-binding of c-MET and EGFR to JNJ-61186372 was analyzed by SPR using the ProteOn XPR instrument. About 140 resonance units of c-MET-Fc chimera bearing a His tag was captured on nickel-activated HTG sensor chip surface. The recombinant human HGF receptor/c-MET-Fc-His capture was followed by co-injection of JNJ-61186372 (injection 1), followed by serially diluted EGFR monomer (injection 2). The co-injection was performed at a flow rate of 50 µl/min for 216 s. The dissociation was monitored for 900 s. Regeneration of the capture surface was performed using 300 mM EDTA, pH 8.5 (Bio-Rad), at a flow rate of 30 µl/min and 800-s contact time. Before the next capture was performed, 60 s of PBS buffer containing Tween 20 (Bio-Rad) was injected at 100 µl/min flow rate. Data were analyzed with ProteOn Manager™ software version 3.1. Capture levels were determined by grouping all sensorgrams by ligands and creating a report point where the average was taken for ~10 s at the end of the injection for capture. Ligand channel reference was achieved by subtracting the signal from an empty ligand (buffer only) channel. A double correction was then performed using the analyte channel with anti-EGFR or c-MET Abs or the bispecific Ab only. The injection start point for the JNJ-61186372 was re-adjusted to start at zero at ~200 s into the run time. The data were then fitted using a Langmuir 1:1 interaction model. The kinetic rate constants, k_{on} and k_{off}, were derived for each reaction. K_D was calculated from the k_{on}/k_{off} ratio.

Conjugation of Abs with (R)-Phycocerythrin (R-PE)—Abs were conjugated to R-PE (ProZyme) using heterobifunctional chemistry. The R-PE was activated using sulfo-sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid (Pierce) for
Relative Antigen Levels Affect Bispecific Antibody Behavior

60 min. Activated R-PE was separated from free sulfo-sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate by gel filtration chromatography. The Abs were reduced using dithiothreitol (DTT, Sigma) for 30 min. The reduced Abs were separated from free DTT by gel filtration chromatography. The activated R-PE was covalently coupled to the reduced Abs for 90 min. The reaction was quenched with N-ethylmaleimide (Fluka) for 20 min. The PE-conjugated Abs were purified by size-exclusion chromatography (SEC) using a Tosoh TSKgel G3000SW column in 100 mM sodium phosphate, 100 mM sodium sulfate, 0.05% sodium azide, pH 6.5, on an AKTA explorer FPLC system. The R-PE-conjugated Abs were stored at 2–8 °C in light-occlusive containers. For analytical SEC, the pooled fractions were applied to a Tosoh TSKgel G3000SWx1 column in 100 mM sodium phosphate, 100 mM sodium sulfate, 0.05% sodium azide, pH 6.5. The samples were quantified by absorbance at 280 nm normalized for the contribution of conjugated R-PE using Equation 1,

\[
\text{Ab concentration (M) = } \left( \frac{A_{280} - (A_{565} \times \text{correction factor})}{e} \right) \times \text{dilution factor (Eq. 1)}
\]

where \(A_{280}\) is the absorbance value at 280 nm of the Ab-PE conjugate; \(A_{565}\) is the absorbance value at 565 nm of the Ab-PE conjugate; the correction factor equals the \(A_{280}/A_{565}\) of a PE solution, and \(e\) is the extinction coefficient of the Ab at 280 nm. The 1:1 labeling ratio was confirmed using Equation 2,

\[
\text{molar ratio (PE/Ab) = } \left( \frac{A_{565}/(e' \times \text{Ab concentration (M))}}{\text{dilution factor}} \right) \times \text{dilution factor (Eq. 2)}
\]

where \(A_{565}\) is the absorbance value at 565 nm of the Ab-PE conjugate, and \(e'\) is the molar extinction coefficient value of the fluorescent dye. Following quantitation, samples were diluted to 40 µg/ml working stocks in PBS, pH 7.5, with 0.5% BSA and 0.1% (w/v) NaN3 plus 0.01% (w/v) Silwet (Momentive Performance). Confirmation of the free R-PE component was determined using Equation 3,

\[
\% \text{ free PE} = \left( \frac{100 \times \text{Free PE peak area}}{\text{total Ab-PE conjugate peak area}} \right) \times 100\% \quad \text{(Eq. 3)}
\]

where the peak areas are determined by analytical SEC.

Flow Cytometry Staining—Immediately following dissociation, the cells were assessed for viability by exclusion of 0.4% (w/v) trypan blue (Life Technologies, Inc.). Cell number and viability were calculated using a C-chip hemocytometer (Incyto, Covington, GA). Cells were resuspended at 1 × 10⁶ cells/ml in BSA Stain Buffer (BD Biosciences), from which point cells were rigorously kept at 4 °C to prevent receptor internalization. Fixation of cells was avoided due to the potential effects of paraformaldehyde on Ab dissociation rates and/or epitope integrity (28, 38). Fc receptors (although reportedly not present on these cells) were blocked with 5 µl per test of human TruStain FeX™ (BioLegend, San Diego) for 30 min at 4 °C. Cells (1 × 10⁷ per well) were transferred to 96-well V-bottom microplates (Greiner, Monroe, NC). Cells were incubated on ice for 1 h with serial dilutions of in-house R-PE-labeled c-MET, EGFR, or mN1-61186372 at empirically determined saturating concentrations. Commercial Abs used included anti-human HGF/c-MET-PE (R&D Systems, Minneapolis, WI) and anti-human EGFR-PE (BioLegend, San Diego). Isotype-matched controls included mouse IgG1i control-PE (R&D Systems) and mouse IgG2b/k isotype control-PE (BioLegend, San Diego). Isotype controls were applied to cells at the highest concentration used for the respective receptor-specific Ab. Cells were washed twice with 150 µl of BSA Stain Buffer and resuspended in 250 µl of BSA Stain Buffer containing 1:50 diluted DRAQ7 live/dead stain (Cell Signaling Technology, Danvers, MA). Single stain controls for PE and DRAQ7 were also included. Samples were read on either a FACScalibur (BD Biosciences) or MACSQuant flow cytometer (Miltenyi Biotec, Auburn, CA). The data collection channels for PE/DRAQ7 were as follows: FL2/FL4 (FACScalibur) and B2/B4 (MACSQuant). Live cells were gated on DRAQ7 exclusion, and the geometric mean fluorescence intensity (MFI) was determined for at least 5000 live events collected at a low flow rate. FlowJo vX software (Tree Star Inc.) was used for analysis.

Determination of Antigen Density—Receptor density values are reported as the ABC. ABC values were derived from standard curves generated with QuantiBRITE™ PE beads (BD Biosciences). QuantiBRITE™ PE beads consist of four populations of microspheres that are each conjugated to a distinct number of PE molecules per bead, as developed by Iyer et al. (28). The beads were run on the same day and at the same photomultiplier tube settings as the test samples. The QuantiBRITE™ PE beads were evaluated as a biological calibrator against CD4 on human T cells using PE-Leu3a (BioLegend) and found to approximate previously reported ABC values (25, 38). The Quantum™ (R)-PE MESF (Bangs Laboratories, Inc., Fishers, IN) and Quantum™ Simply Cellular™ anti-mouse IgG (Bangs Laboratories, Inc.) were used to empirically confirm the reported 1:1 F/P ratio of the commercial EGFR and c-MET Abs. To calculate ABC values, the geometric means for the four QuantiBRITE™ PE singlet bead populations were derived in FlowJo. Linear regression was used to create a standard curve in GraphPad Prism 6 (GraphPad Software, Inc.) of the log10(number of PE molecules/bead) versus the log(MFI). \(R^2\) values were typically ≥0.99. ABC values for the PE-Abs were interpolated from the Quanti-BRITE™ PE standard curve. ABC values presented here are the specific antibody binding capacity calculated by subtracting the ABC values from an isotype-matched control from the ABC of the EGFR or c-MET Abs, rounded to three significant figures.

Heterodimerization and Homodimerization Enzyme Fragment Complementation Assay—The EGFR homodimerization and EGFR/c-MET heterodimerization assays were carried using PathHunter® enzyme fragment complementation (EFC) technology (40, 41). Briefly, the extracellular domains of c-MET(1–960) and EGFR(1–679) were C-terminally fused to a complementary inactive fragment of β-galactosidase (β-gal) using standard molecular biology techniques. Constructs were transfected into parental U-2 OS (U2OS) cells purchased from ATCC. Stably transfected U-2 OS clones were analyzed for
Relative Antigen Levels Affect Bispecific Antibody Behavior

expression and membrane localization by flow cytometry using PE-labeled anti-EGFR and anti-c-MET Abs. For the EFC assays, cells were plated in quadruplicate in 20 μl of assay media on 384-well plates with 5000 cells/well. Test compounds were serially diluted 1:3 in 0.1% bovine serum albumin (BSA)/PBS such that the highest concentration applied was 10 μg/ml. Recombinant human epidermal growth factor (EGF) and hepatocyte growth factor (HGF) stock solutions were diluted in the same manner as the Abs. EGFR homodimer and c-MET homodimer cell lines were also constructed as positive controls for PathHunter technology and to demonstrate specificity. Treatment-induced heterodimerization or homodimerization of recombiant receptors tagged with complementary β-gal fragments resulted in regeneration of fully functional enzyme whose activity can be monitored via chemiluminescence. Incubations were carried out for 6 h at room temperature. PathHunter® flash detection reagent was added to cells, followed by a 60-min incubation at room temperature. Luminescence, reported as relative light units, was recorded on an EnVision Multilabel Reader (PerkinElmer Life Sciences) at 1 count/s. Nonlinear regression analysis was performed in GraphPad Prism 6 (GraphPad Software, Inc.) using a four-parameter logistic (4PL) model with no constraints. For conversions of g/ml to nanomolar, was recorded on an EnVision Multilabel Reader (PerkinElmer Life Sciences) at 1 count/s. Nonlinear regression analysis was performed in GraphPad Prism 6 (GraphPad Software, Inc.) using a four-parameter logistic (4PL) model, and data from multiple experiments were used to calculate mean IC_{50} ± S.E., rounded to two significant figures.

mRNA Expression Profiling—Expression profiling was performed by GeneWiz, Inc. (South Plainfield, NJ), using a quantitative real-time PCR assay. RNA was extracted from cell pellets of NSCLC samples and normal lung cells using the RNeasy Plus mini kit (Qiagen). The concentration, A_{260}/A_{280} UV absorbance ratio, and A_{260}/A_{230} UV absorbance ratio of the RNA samples were measured by NanoDrop (Thermo Scientific). Complementary DNA was generated from each RNA sample using the high capacity cDNA reverse transcription kit (Invitrogen). Quantitative PCR assays, consisting of primers and probes used to detect EGFR, c-MET, and B2M (reference control gene) were purchased from Life Technologies, Inc. Quantitative polymerase chain reactions were assembled in 384-well plates using TaqMan® PCR Master Mix (Life Technologies, Inc.). Each PCR assay was multiplexed with the B2M assay in a 10-μl reaction containing 0.9 μM forward and reverse primers, 0.25 μM each probe, and 4 ng of cDNA. Amplification consisted of single cycles of 2 min at 50 °C and 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C, 1 min at 60 °C. Reactions were performed on the 7900HT Real Time PCR instrument (Applied Biosystems). Each sample was assayed in four replicate wells. The data were analyzed using Applied Biosystems software “Sequence Detection Systems™” Version 2.4.1. A manual threshold of 0.2 was used, and automatic baseline was applied. Data from outlier wells were excluded from the analysis. ΔCT (cycle threshold) values were calculated based on the mean CT values of the target genes and mean CT values of the reference control gene B2M, using Equation 4,

$$\Delta CT = \text{mean CT for target gene} - \text{mean CT for B2M}$$

(Eq. 4)

Relative gene expression levels were calculated using ΔΔCT analysis and the normal lung as the calibrator sample as shown in Equation 5.

$$\Delta\Delta CT = \Delta CT \text{ of sample} - \Delta CT \text{ of calibrator}$$

(Eq. 5)

Results

Generation of Bispecific Abs for Receptor Quantitation and In Vitro Characterization—In this work, we sought to generate optimal reagents for quantifying EGFR and c-MET cell-surface expression and evaluating the target engagement of a BsAb (IN)-61186372 targeting these two receptors. Because the stoichiometry of Ab binding cannot be predicted and because the impact of valency and avidity on the accuracy of receptor quantitation measurements have been well documented (38, 39), we chose to use a monovalent Ab system for quantitation. Additionally, understanding how a BsAb engages both its cell-surface targets can be challenging. Here, we harnessed the utility of cFAE technology for studies of both receptor quantitation and target engagement. We have taken high affinity anti-c-MET and anti-EGFR Abs and used cFAE to create BsAbs of >95% purity with >95% yield incorporating the following Fab arm
Relative Antigen Levels Affect Bispecific Antibody Behavior

A  c-Met  c-Met  B  EGFR  EGFR  EGFR  c-Met
D  gp120  c-Met  gp120  E  EGFR  gp120

FIGURE 1. Schematic of antibody molecules for receptor quantitation and target engagement studies. A, α-c-MET bivalent parental mAb; B, α-EGFR bivalent parental Ab; C, α-EGFR × α-c-MET BsAb (JNJ-61186372); D, α-c-MET monovalent BsAb; and E, α-EGFR monovalent BsAb. The domains were colored as follows: blue, α-c-MET; orange, α-EGFR; green, α-gp120.

Table 1 introduces a degree of error into receptor quantitation calculations. In addition to its large size (240 kDa), which facilitates purification of unimolar labeled conjugates, the spectral characteristics of R-PE, which include a high quantum efficiency, high stain index, large Stokes shifts, and resistance to quenching, make it an ideal candidate for quantitative studies (38, 42). The use of R-PE conjugated in a 1:1 molar ratio to an Ab significantly improves the accuracy of QFCM methods (43). The percent recovery of this highly homogeneous purified material was ~10%.

EGFR and c-MET Receptor Quantitation—We determined EGFR and c-MET expression levels on a panel of 11 tumor cell lines using QFCM. The determination of ABC was derived from a standard curve established by QuantibRITE™ PE beads. ABC values were determined for c-MET (Table 2) and EGFR (Table 3) using PE-labeled monovalent or bivalent Abs. As part of our initial investigation on the impact of valency on ABC value, we performed quantitative comparisons of monovalent versus bivalent EGFR and c-MET IgGs. Results showed that, at saturation, the monovalent Ab always gave a higher MFI value, and hence a greater ABC value (Fig. 4A).

Although saturation was achieved for R-PE-c-MET Abs on all NSCLC cell lines, the R-PE-labeled EGFR Abs could not achieve saturation in all instances. When saturation could not be achieved, the maximum fluorescence intensity predicted by regression analysis of the logarithm of antibody concentration versus fluorescence was used for ABC determination. Although the bulky PE adduct could impact the binding of the EGFR Ab due to epitope location, cell line-specific receptor/co-receptor interactions, or some other type of steric hindrance, these labeled Abs had similar maximal MFI values as that of the unlabeled Abs detected by labeled secondary mAbs.

For a panel of seven NSCLC lines (H2935, H1650, HCC4006, H1975, H3255, HCC827, and H820) where direct comparisons were performed, the average Ab binding capacity of the bivalent c-MET Ab was 76.3 ± 6.2% of the Ab binding capacity of the monovalent c-MET (Fig. 4B). The difference in ABC values between the monovalent and bivalent parental Abs reflects the stoichiometry or avidity of Ab binding. Our preliminary results agreed with earlier studies by Davis et al. (38) who compared Ab and Fab binding to CD4 antigen on T cells or latex beads and found that the valency of binding was independent of antigen density. However, avidity can result in occlusion of receptor binding that prevents maximal binding of Abs on the cell surface. Likewise, we determined that the levels of monovalent Ab binding levels were higher than that of bivalent Ab binding. To most accurately phenotype the NSCLC lines for EGFR and c-MET, we assigned values for each receptor based on the monovalent Ab, which theoretically provides the most reliable estimate of the number of epitopes per cell.

Analytical HPLC of unimolar purified conjugates showed purities of ≥95% (Fig. 3). Commercially available Abs conjugated to a fluorochrome can be heterogeneous due to variable labeling and purity. Depending on the choice of fluorochrome and method of conjugation, the number of fluorochrome molecules conjugated to each Ab molecule can vary, and an F/P molar ratio of >1 introduces a degree of error into receptor quantitation. Therefore, as conjugation efficiency, high stain index, large Stokes shifts, and resistance to quenching, make it an ideal candidate for quantitative studies (38, 42). The use of R-PE conjugated in a 1:1 molar ratio to an Ab significantly improves the accuracy of QFCM methods (43). The percent recovery of this highly homogeneous purified material was ~10%.

**EGFR and c-MET Receptor Quantitation**—We determined EGFR and c-MET expression levels on a panel of 11 tumor cell lines using QFCM. The determination of ABC was derived from a standard curve established by QuantibRITE™ PE beads. ABC values were determined for c-MET (Table 2) and EGFR (Table 3) using PE-labeled monovalent or bivalent Abs. As part of our initial investigation on the impact of valency on ABC value, we performed quantitative comparisons of monovalent versus bivalent EGFR and c-MET IgGs. Results showed that, at saturation, the monovalent Ab always gave a higher MFI value, and hence a greater ABC value (Fig. 4A).

Although saturation was achieved for R-PE-c-MET Abs on all NSCLC cell lines, the R-PE-labeled EGFR Abs could not achieve saturation in all instances. When saturation could not be achieved, the maximum fluorescence intensity predicted by regression analysis of the logarithm of antibody concentration versus fluorescence was used for ABC determination. Although the bulky PE adduct could impact the binding of the EGFR Ab due to epitope location, cell line-specific receptor/co-receptor interactions, or some other type of steric hindrance, these labeled Abs had similar maximal MFI values as that of the unlabeled Abs detected by labeled secondary mAbs.

For a panel of seven NSCLC lines (H2935, H1650, HCC4006, H1975, H3255, HCC827, and H820) where direct comparisons were performed, the average Ab binding capacity of the bivalent c-MET Ab was 76.3 ± 6.2% of the Ab binding capacity of the monovalent c-MET (Fig. 4B). The difference in ABC values between the monovalent and bivalent parental Abs reflects the stoichiometry or avidity of Ab binding. Our preliminary results agreed with earlier studies by Davis et al. (38) who compared Ab and Fab binding to CD4 antigen on T cells or latex beads and found that the valency of binding was independent of antigen density. However, avidity can result in occlusion of receptor binding that prevents maximal binding of Abs on the cell surface. Likewise, we determined that the levels of monovalent Ab binding levels were higher than that of bivalent Ab binding. To most accurately phenotype the NSCLC lines for EGFR and c-MET, we assigned values for each receptor based on the monovalent Ab, which theoretically provides the most reliable estimate of the number of epitopes per cell.
Cell Culture and Time-dependent Changes in Receptor Expression—The impact of cell culture conditions, confluence, and passage number on expression levels has been previously described (39, 44). In this study, we have rigorously standardized cell culture procedures to minimize these sources of variability (see “Experimental Procedures”). The cell culture conditions used for the determination of receptor density, mRNA expression levels, and phosphorylation inhibition assays were identical. However, given the transformed nature of the NSCLC cell lines, some fluctuation in expression over time must be expected. The reproducibility of the EGFR and c-MET receptor ABC values varied by cell type and are listed in Tables 2 and 3.

Correlation of EGFR and c-MET mRNA Gene Expression to Receptor Density—We performed expression profiling analysis of EGFR and c-MET for 11 NSCLC cell lines, and we normalized the values to the corresponding values measured in primary human lung fibroblasts (Table 4). Cell lines with amplified c-MET genes exhibited significantly higher mRNA levels than those with WT gene levels of c-MET (Tables 1 and 4). Normalized c-MET mRNA levels for H820, SNU-5, and H1993 were 52-, 42-, and 136-fold, respectively, whereas the WT cell lines ranged from 1- to 22-fold. Cell lines with the largest EGFR copy number, H3255 and HCC827 (Table 1), had the highest mRNA levels, 73- and 97-fold, respectively. However, not all EGFR-amplified cell lines showed EGFR mRNA levels higher than those with WT EGFR. WT EGFR mRNA levels ranged from 2- to 8-fold. Gene expression levels for both EGFR (Fig. 5A) and c-MET (Fig. 5B) did correlate in a statistically significant manner to receptor density ABC values. Pearson correlation coefficient for the c-MET gene-receptor density plot resulted in a p value of 0.0007 and an r^2 of 0.7368. Pearson correlation coeffi-
cient for the EGFR gene-receptor density plot gave a \( p \) value of 0.0075 and \( r^2 \) of 0.5663.

**Correlation of JNJ-61186372-mediated Inhibition of Receptor Phosphorylation to Receptor Density**—We determined IC\(_{50}\) values for the ability of JNJ-61186372 to block ligand-induced receptor phosphorylation of EGFR and c-MET on the panel of cell lines (Table 5). Representative dose responses are shown in Figs. 6–8. There was a correlation between normalized EGFR ABC values and the IC\(_{50}\) values of JNJ-61186372 against EGFR phosphorylation with a Pearson correlation coefficient \( p \) value of 0.0074 and an \( r^2 \) value of 0.7903 (Fig. 6A). There was also a correlation between the normalized c-MET ABC and the IC\(_{50}\) values of JNJ-61186372 against c-MET phosphorylation with a Pearson correlation coefficient \( p \) value of <0.0001 and an \( r^2 \) value of 0.9331 (Fig. 6B). In other words, the potency of inhibition of receptor phosphorylation by JNJ-61186372 was proportional to the receptor density for both EGFR and c-MET.

**JNJ-61186372 Heterodimerizes EGFR and c-MET**—U-2 OS cells were stably transfected with EGFR and c-MET receptors genetically fused to complementary fragments of -gal and optimized for expression. EFC assays were carried out by incubating the cells with serially diluted concentrations of either c-MET monovalent Ab, c-MET bivalent Ab, EGFR monovalent Ab, c-MET monovalent Ab, EGF, HGF, or bispecific JNJ-61186372. The samples were assessed for their ability to heterodimerize EGFR and c-MET as measured by -gal activity. Treatment of the stably transfected U-2 OS cells with JNJ-61186372 elicited a significant dose-dependent increase in chemiluminescence (Fig. 7A) with a half-maximal effective concentration (EC\(_{50}\) of 142 ± 19.6 pm). The signal-to-noise (S/N) ratio for JNJ-61186372 in this...
Relative Antigen Levels Affect Bispecific Antibody Behavior

**TABLE 3**

| ABC values for EGFR | PE-EGFR × gp120 | PE-EGFR | n |
|---------------------|------------------|----------|
| Cell line           | Mean             | S.E.     | n  |
| H1975               | 6.32 × 10^4      | 2.56 × 10^4| 3  |
| HCC827              | 4.01 × 10^4      | 1.27 × 10^4| 2  |
| H1650               | 1.21 × 10^4      | 1741^a   | 1  |
| H3255               | 8.23 × 10^4      | 15,039^a | 1  |
| H820                | 1.11 × 10^4      | 1.41 × 10^4| 2  |
| H2935               | 1.34 × 10^4      | 15,428^a | 1  |
| HCC4006             | 9.09 × 10^4      | 7852^a   | 1  |
| H1993               | 3.25 × 10^4      | 7.99 × 10^4| 4  |
| H292                | 3.57 × 10^4      | 8.27 × 10^4| 2  |
| SKMES-1             | 1.67 × 10^4      | 7.72 × 10^4| 2  |
| SNU-5               | 1.11 × 10^4      | 6.96 × 10^4| 3  |

| Cell line | Mean | S.E. | n  |
|------------|------|------|----|
| H1975      | 5.84 × 10^4 | 2.01 × 10^4| 3  |
| HCC827     | 3.48 × 10^4 | 1.35 × 10^4| 4  |
| H1650      | 9.63 × 10^4 | 8.45 × 10^4| 3  |
| H3255      | 7.39 × 10^4 | 3.19 × 10^4| 4  |
| H820       | 9.25 × 10^4 | 5.60 × 10^4| 2  |
| H2935      | 8.24 × 10^4 | 4380^b  | 1  |
| HCC4006    | 5.05 × 10^3 | 1850^a  | 1  |
| H1993      | ND    | ND   | ND |
| H292       | ND    | ND   | ND |
| SKMES-1    | ND    | ND   | ND |
| SNU-5      | ND    | ND   | ND |

* S.E. for n = 1 was derived from nonlinear regression analysis of antibody concentration versus MFI. ND means not determined.

**TABLE 4**

| Relative mRNA levels of EGFR and c-MET | 2^(-ΔΔCT) | 2^(-ΔΔCT) |
|----------------------------------------|-----------|-----------|
| Cell line                              | EGFR      | c-MET     |
| H1993                                  | 8.2       | 136.3     |
| A549                                   | 3.0       | 7.8       |
| H292                                   | 12.1      | 11.2      |
| Normal Lung                            | 1.0       | 1.0       |
| SKMES-1                                | 5.2       | 7.1       |
| SNU-5                                  | 2.2       | 42.0      |
| H3255                                  | 72.7      | 13.1      |
| H1997                                  | 5.1       | 5.2       |
| HCC4006                                | 6.3       | 5.3       |
| H1650                                  | 7.7       | 6.1       |
| HCC827                                 | 96.9      | 21.6      |
| H820                                   | 5.0       | 51.5      |
| HCC2935                                | 0.5       | 1.3       |

* See under “Experimental Procedures” for 2^(-ΔΔCT) calculations.

assay was ~2.8-fold. The combination of the single arm binding BsAbs had lower responses. Interestingly, HGF may also heterodimerize EGFR and c-MET but, at a S/N of ~1.4, to a much lesser extent than JNJ-61186372 (Fig. 7B).

EGFR and c-MET homodimerization assays were also developed to validate the PathHunter® technology. A dose-dependent increase in β-gal activity was seen in response to EGF binding (EC_{50} of 10.1 ng/ml or 1.62 nM), with a S/N of ~2.4. However, no EGFR homodimerization was evident upon incubation with any of the c-MET, EGFR Abs, or JNJ-61186372 (Fig. 7, E and F). No c-MET homodimerization was detected upon incubation with EGF and EGFR only Abs or BsAbs (Fig. 7, C and D). There was high level of c-MET dimerization upon addition of HGF (EC_{50} of 0.257 μg/ml or 3.21 nM), lower levels with bivalent c-MET mAb, but even lower levels of homodimerization upon incubation with JNJ-61186372 and monovalent c-MET BsAbs (gp120 × c-MET and the combination of gp120 × c-MET BsAb + EGFR × gp120 BsAb).

**Avidity Effect of BsAbs in Inhibition of Receptor Phosphorylation**—We also evaluated the potency with which JNJ-61186372 blocks ligand-induced receptor phosphorylation relative to c-MET × gp120 BsAbs, EGFR × gp120 BsAbs, or combinations of monovalent EGFR and c-MET BsAbs, in cell lines with different ratios of EGFR to c-MET expression. The ABC values for EGFR and c-MET in H292, H1993, and SNU-5 are reported in Tables 2 and 3. The Abs used in these comparisons were not PE-labeled.

Results showed that in H292 where the EGFR/c-MET ABC ratio was measured at ~5.8 (Tables 2 and 3), the IC_{50} value of JNJ-61186372 in blocking c-MET receptor phosphorylation was 0.86 ± 0.067 nM, ~5-fold lower than the IC_{50} value of c-MET × gp120 BsAb, which was 4.1 ± 0.15 nM (Fig. 8A). There was no inhibitory effect by the gp120 mAb and minimal inhibitory effect of EGFR × gp120 BsAb on c-MET phosphorylation. The small inhibitory effect of EGFR × gp120 BsAb on c-MET phosphorylation may be due to cross-talk between the two receptors. EGFR signaling has been shown to enhance HGF-induced c-MET phosphorylation levels in lung cancer cell lines (21). Additionally, the combination of EGFR × gp120 BsAb + c-MET × gp120 BsAb exhibited a limited increase in potency in blocking c-MET receptor phos-
phorylation relative to the c-MET gp120 BsAb alone. The IC$_{50}$ value of the EGFR × gp120 BsAb + c-MET × gp120 BsAb was 2.8 nM.

Interestingly, there was no increase in the potency of JNJ-61186372 in H292 in blocking EGF receptor phosphorylation relative to the EGFR gp120 Ab BsAb alone (Fig. 8B). JNJ-61186372 had an IC$_{50}$ value of 29 nM, whereas the EGFR × gp120 BsAb had an IC$_{50}$ value of 13 ± 1.1 nM. There was no difference in potency between the EGFR × gp120 BsAb alone and the combination of EGFR × gp120 + c-MET × gp120, which also had an IC$_{50}$ value of 13 nM. There was no inhibitory effect on EGFR phosphorylation for gp120 mAb or gp120 c-MET BsAb. JNJ-61186372 therefore shows an increase in potency for c-MET phosphorylation inhibition and no increase in potency for EGFR phosphorylation inhibition in H292 where the EGFR receptor density is greater than the c-MET receptor density.

### TABLE 5

Inhibition of receptor phosphorylation

IC$_{50}$ (values in nM) are calculated using GraphPad Prism 6 software. NF indicates no fit is used when either Prism does not return a value (e.g. “ambiguous”) or the fit is poor (95% confidence interval range is >4-fold). ND = not determined.

| Molecule and receptor                        | H292 | SNU-5 | H1993 |
|---------------------------------------------|------|-------|-------|
| IC$_{50}$ S.E. n                           | IC$_{50}$ S.E. n | IC$_{50}$ S.E. n |
| JNJ-61186372                                |      |       |       |
| Phosphorylated EGFR                         | 15   | 3.8   | 2     |
| Phosphorylated c-MET                        | 2.8  | 2.6   | 3     |
| EGFR × gp120                                |      |       |       |
| Phosphorylated EGFR                         | NF   | NF    | 2     |
| Phosphorylated c-MET                        | NF   | NF    | 2     |
| c-MET × gp120                               |      |       |       |
| Phosphorylated EGFR                         | NF   | NF    | 2     |
| Phosphorylated c-MET                        | NF   | NF    | 2     |
| EGF × gp120 + c-MET × gp120                 |      |       |       |
| Phosphorylated EGFR                         | NF   | NF    | 2     |
| Phosphorylated c-MET                        | NF   | NF    | 2     |

FIGURE 5. Correlation of relative gene expression ($2^{-\Delta\DeltaCT}$) to receptor quantitation. A, mRNA levels for EGFR plotted versus EGFR ABC. Pearson correlation method results are $p = 0.0075$ and $r^2 = 0.5663$. B, mRNA levels for c-MET plotted versus c-MET ABC. Pearson correlation method results are $p = 0.0007$ and $r^2 = 0.7368$.

FIGURE 6. Correlation of inhibition of receptor phosphorylation to receptor quantitation. A, IC$_{50}$ values for JNJ-61186372-mediated inhibition of EGFR phosphorylation plotted versus EGFR ABC. Pearson correlation method results are $p = 0.0074$ and $r^2 = 0.7903$. B, IC$_{50}$ values for JNJ-61186372-mediated inhibition of c-MET phosphorylation plotted versus c-MET ABC. Pearson correlation method results are $p < 0.0001$ and $r^2 = 0.9331$. 

### Note

- **IC$_{50}$** values for JNJ-61186372-mediated inhibition of EGFR phosphorylation plotted versus EGFR ABC. Pearson correlation method results are $p = 0.0074$ and $r^2 = 0.7903$.
- **IC$_{50}$** values for JNJ-61186372-mediated inhibition of c-MET phosphorylation plotted versus c-MET ABC. Pearson correlation method results are $p < 0.0001$ and $r^2 = 0.9331$. 

**A**, mRNA levels for EGFR plotted versus EGFR ABC. Pearson correlation method results are $p = 0.0075$ and $r^2 = 0.5663$. **B**, mRNA levels for c-MET plotted versus c-MET ABC. Pearson correlation method results are $p = 0.0007$ and $r^2 = 0.7368$. 

**TABLE 5**

Inhibition of receptor phosphorylation

IC$_{50}$ (values in nM) are calculated using GraphPad Prism 6 software. NF indicates no fit is used when either Prism does not return a value (e.g. “ambiguous”) or the fit is poor (95% confidence interval range is >4-fold). ND = not determined.
We also compared these results with cell lines that have an inverse relationship of ABC values of EGFR and c-MET receptor densities. In SNU-5 cells, where the EGFR/c-MET-specific ABC ratio was measured at $0.2$ (Tables 2 and Table 3), the IC$_{50}$ value of JNJ-61186372 in blocking EGFR receptor phosphorylation was $15 \pm 2.8$ nm, whereas no IC$_{50}$ value could be derived from the EGFR × gp120 titration (Fig. 9B). The combination of EGFR × gp120 + c-MET × gp120 did...
Relative Antigen Levels Affect Bispecific Antibody Behavior

**FIGURE 8. Inhibition of ligand-induced receptor phosphorylation in H292 cells.** The ratio of EGFR to c-MET ABC values in H292 as measured by QFCM was 5.72-fold. 4PL indicates curve-fitting of log_{10} of Ab concentration versus ECL. Inhibition of c-MET phosphorylation relative to an HGF-treated control by EGFR × gp120 BsAb (blue ø), gp120 × c-MET BsAb (green ■), gp120 × c-MET BsAb + EGFR × gp120 BsAb (orange ▼), and JNJ-61186372 (EGFR × c-MET) BsAb (red △), or gp120 mAb (gray ♦) is shown (A). Inhibition of EGFR phosphorylation relative to an EGFR-treated control by EGFR × gp120 BsAb (blue ø), gp120 × c-MET BsAb (green ■), gp120 × c-MET BsAb + EGFR × gp120 BsAb (orange ▼), and JNJ-61186372 (EGFR × c-MET) BsAb (red △), or gp120 mAb (gray ♦) is shown (B).

**FIGURE 9. Inhibition of ligand-induced receptor phosphorylation in SNU-5 cells.** The ratio of EGFR to c-MET ABC in SNU-5 as measured by QFCM was 0.2-fold. 4PL indicates curve-fitting of log_{10} of Ab concentration versus ECL. Inhibition of c-MET phosphorylation relative to an HGF-treated control by EGFR × gp120 BsAb (blue ø), gp120 × c-MET BsAb (green ■), gp120 × c-MET BsAb + EGFR × gp120 BsAb (orange ▼), and JNJ-61186372 (EGFR × c-MET) BsAb (red △), or gp120 mAb (gray ♦) is shown (A). Inhibition of EGFR phosphorylation relative to an EGFR-treated control by EGFR × gp120 BsAb (blue ø), gp120 × c-MET BsAb (green ■), gp120 × c-MET BsAb + EGFR × gp120 BsAb (orange ▼), and JNJ-61186372 (EGFR × c-MET) BsAb (red △), or gp120 mAb (gray ♦) is shown (B).

have a slight inhibitory effect on EGFR phosphorylation, although an IC_{50} value could not be derived. Because of the high levels of c-MET present, there was a high background of c-MET phosphorylation activity (Fig. 9A). In fact, no IC_{50} values could be generated for blocking c-MET receptor phosphorylation in SNU-5.

We performed the same experiments in H1993 cells where the EGFR density is less than that of c-MET, as in SNU-5 cells. In H1993 cells, the EGFR/c-MET ABC ratio was measured at ~0.6 (Tables 2 and 3). The IC_{50} value of JNJ-61186372 in blocking EGFR phosphorylation was 3.8 ± 0.22 nM, which was 2.6-fold lower than the IC_{50} value of EGFR × gp120 alone, which was 10 ± 0.15 nM (Fig. 10A). There was no inhibitory effect of the c-MET × gp120 BsAb and gp120 mAb alone on EGFR phosphorylation. The IC_{50} value of the EGFR × gp120 BsAb + c-MET × gp120 BsAb combination was 9.2 ± 0.21 nM, slightly more potent at blocking EGFR phosphorylation than EGFR × gp120 BsAb alone. The IC_{50} value of JNJ-61186372 at blocking c-MET receptor phosphorylation was 7.8 ± 2.6 nM, nearly identical to the IC_{50} value of c-MET × gp120 BsAb alone, which was 7.8 nM. The IC_{50} value of the EGFR × gp120 BsAb + c-MET × gp120 BsAb combination on blocking c-MET receptor phosphorylation was 12 nM (Fig. 10B). There was no inhibitory effect of the EGFR × gp120 BsAb alone or gp120 mAb on c-MET phosphorylation. In summary, JNJ-61186372 shows an increase in potency for EGFR phosphorylation inhibition and no increase in potency for c-MET phosphorylation inhibition in SNU-5 and H1993 cells where the c-MET receptor density is greater than the EGFR density. In conclusion, the increase in BsAb phosphorylation inhibition levels follow the relative ratios of the target receptors on a cell surface.

**JNJ-61186372 Binding to Cells Is Guided by the More Highly Expressed of Its Two Targeted Receptors**—In an attempt to understand how a BsAb engages its surface targets, we performed comparative binding flow cytometry titrations with JNJ-61186372, c-MET × gp120 BsAb, and the EGFR × gp120 BsAb against multiple cell lines. We used unlabeled primary Abs followed by PE-labeled secondary Ab detection. A qualitative examination of the binding curves revealed an interesting pattern. The JNJ-61186372 curves approximate the curve of the monovalent Ab corresponding to the more highly expressed receptor in a given cell line (Fig. 11, A and B). In Fig. 11A, JNJ-61186372 was more potent in binding than the monovalent EGFR × gp120 and c-MET × gp120 BsAbs. In Fig. 11A, the ABC EGFR/ABC c-MET ratios were 10.7 for H292; 6.1 for H3255 and 3.6 of SKMES-1; and 2.0 for HCC827. Thus, the cell
binding profiles were more similar to binding to EGFR alone as exemplified by the binding profiles of EGFR/H11003 gp120 BsAbs as compared with that of c-MET/H11003 gp120. Conversely, in Fig. 11B, JNJ-61186372 was more potent or equipotent in binding than the monovalent EGFR/H11003 gp120 and c-MET/H11003 gp120 BsAbs. In Fig. 11B, the ABC EGFR/ABC c-MET ratios were 0.22 for SNU-5; 0.62 for H820 and 0.58 of H1993; and 0.72 for H1975. Thus, the cell binding profiles were more similar to binding to c-MET alone as exemplified by the binding profiles of c-MET/H11003 gp120 BsAbs as compared with that of EGFR/H11003 gp120. The greater the specific ABC difference between EGFR and c-MET, the more clearly this pattern is evident. There appears to be saturation of binding for JNJ-61186372 that is not much greater than that of the respective single arm BsAb. However, this pattern was less discernible for the H2935, H1650, and HCC4006 where the ABC EGFR/ABC c-MET ratios were 3.1 for H2935; 2.1 for H1650 and 1.6 for HCC4006 (Fig. 11C). For these cell lines, there were lower levels of c-MET ABC values as compared with cell lines that were

FIGURE 10. Inhibition of ligand-induced receptor phosphorylation in H1993 cells. The ratio of EGFR to c-MET ABC in H1993 as measured by QFCM was 0.6-fold. 4PL indicates curve-fitting of log_{10} of Ab concentration versus ECL. Inhibition of c-MET phosphorylation relative to an HGF-treated control by EGFR × gp120 BsAb (blue ●), gp120 × c-MET BsAb (green ■), gp120 × c-MET BsAb + EGFR × gp120 BsAb (orange ▼), and JNJ-61186372 (EGFR × c-MET) BsAb (red ▲), or gp120 mAb (gray ●) is shown (A). Inhibition of EGFR phosphorylation relative to an HGF-treated control by EGFR × gp120 BsAb (blue ●), gp120 × c-MET BsAb (green ■), gp120 × c-MET BsAb + EGFR × gp120 BsAb (orange ▼), and JNJ-61186372 (EGFR × c-MET) BsAb (red ▲), or gp120 mAb (gray ●) is shown (B).

FIGURE 11. Cell binding comparisons of JNJ-61186372 (EGFR × c-MET) BsAb, c-MET/H11003 gp120 BsAb, and EGFR/H11003 gp120 BsAb. 4PL indicates curve-fitting of log of Ab concentration versus MFI. A, cell lines for which JNJ-61186372 approximates EGFR × gp120. B, cell lines for which JNJ-61186372 approximates c-MET × gp120 BsAb. C, cell lines for which JNJ-61186372 binding shows a less discernible pattern. EGFR × gp120 BsAb (blue ●), c-MET × gp120 BsAb (green ■), JNJ-61186372 BsAb (red ▲), IgG1 isotype control (gray ●).
EGFR-driven (H292, H3255, SKMES-1, and HCC827) or c-MET-driven (SNU-5, H820, H1993, and H1975).

Discussion

BsAbs generated by cFAE (Fig. 1) are novel and convenient tools with which to carry out quantitation and comparative binding studies. The incorporation of a nonbinding arm targeting an extraneous antigen obviates the need to switch to an entirely different molecular format (e.g., Fab and scFv) to secure monovalency. This convenience removes potential biases that might occur in comparative studies if disparate spatial configurations impact how the molecules interact with surface targets. cFAE-derived monovalent Abs were labeled with PE and purified to obtain a 1:1 F/P ratio (Fig. 3) for the purpose of quantitation. The latter removes the procedural requirement to account for multiple or heterogeneous labeling when interpreting fluorescence data. By keeping the architecture of the BsAbs, mAbs, and monovalent Abs consistent, we can minimize concerns about the binding and activity data due to changes in spatial geometry.

The SPR assay confirms that JNJ-61186372 can bind to c-MET and EGFR simultaneously (Fig. 2). The EFC assay results (Fig. 7) suggested that JNJ-61186372 could simultaneously engage (i.e., heterodimerize) EGFR and c-MET, which may already be in close proximity on the cell surface. Jo et al. (33) found that EGFR and c-MET co-immunoprecipitated in cancer cells and suggested that their association facilitates the HGF-independent phosphorylation of c-MET through TGFα/EGF-mediated EGFR activation. A thorough investigation of binding stoichiometry for c-MET in a panel of NSCLC cell lines (Fig. 4) showed that cFAE-generated monovalent Abs gave consistently higher ABC values than the bivalent Abs. We propose that, as a result of their 1:1 receptor-binding stoichiometry, the ABC values generated using monovalent Abs more closely approximate the true number of cell-surface epitopes. Although not the primary focus of this study, it should be noted that cFAE provides a unique opportunity to investigate the stoichiometry of binding by allowing a direct comparison between two full-length IgGs, in bivalent and monovalent format.

We found that the receptor numbers were correlated to in vitro inhibition of EGFR and c-MET receptor phosphorylation by EGFR × c-MET bispecific JNJ-61186372 (Fig. 6). Because inhibition of cell-surface receptor phosphorylation is the immediate functional activity mediated by a neutralizing anti-EGFR or anti-c-MET Ab, a methodology that yields reasonably accurate target-receptor quantification should produce this correlation. We found no correlation between receptor density values and the inhibition of downstream signaling in the AKT and ERK pathways (data not shown). Given the complexity and cross-talk in the EGFR and c-MET signaling cascades, the lack of correlation between receptor levels and downstream signaling events is perhaps to be expected. We also found a statistically significant correlation between receptor number and quantitative PCR-determined gene expression (data not shown). However, we realize that intervening post-transcriptional and post-translational regulatory mechanisms may render the latter correlation fortuitous or biologically irrelevant.

The potency with which JNJ-61186372 blocks ligand-induced receptor phosphorylation is greater than that of the corresponding monovalent Ab directed against that receptor. This effect is most pronounced against the less highly expressed of the targeted EGFR/c-MET pair. We have shown this effect against both c-MET (Fig. 8) and EGFR (Figs. 9 and 10) in cell lines in which those receptors were quantitatively determined to be the less highly expressed (Tables 2 and 3). The effect was most pronounced in H292 (Fig. 8), in which EGFR expression is nearly 11-fold greater than that of c-MET. In SNU-5, the inability to block c-MET phosphorylation is likely due to ligand-independent constitutive phosphorylation that results in the high background that cannot result in higher response in the presence of ligand (Fig. 9). The intriguing and unexpected ligand-independent EGFR phosphorylation observed in SNU-5 is perhaps also the result of cross-talk between EGFR and the amplified c-MET (21). We conjectured that the enhanced potency of bispecific JNJ-61186372 relative to monovalent EGFR × gp120 in SNU-5 might be due to receptor degradation. However, neither downstream signaling (pERK and pAKT) nor proliferation was affected by JNJ-61186372 (data not shown). Nonetheless, there was enhanced potency found in EGFR phosphorylation inhibition in H1993 cells that have the ABC EGFR/ABC c-MET ratios of 0.6 (Fig. 10). Thus, JNJ-61186372 enhancement in c-MET phosphorylation inhibition occurred in cell lines with higher EGFR and lower c-MET receptor density levels. But the JNJ-61186372 enhancement in EGFR phosphorylation inhibition occurred in cell lines with lower EGFR and higher c-MET receptor density levels.

We hypothesize that the extent to which JNJ-61186372 interacts with target cells is determined initially by whichever of the two receptors, EGFR or c-MET, is more highly expressed. That initial interaction increases the local cell-surface concentration of the BsAb. Subsequently, it contacts the less highly expressed target, whereupon the dual-receptor avidity results in the balanced, enhanced inhibition of the EGFR/c-MET signaling system that we have observed (Fig. 12). Moreover, JNJ-61186372 may sequester the EGFR and c-MET receptors into a nonsignaling heterodimeric complex that prevents their homodimerization, thus contributing to the increased in vitro potency of JNJ-
61186372 relative to that of the monovalent EGFR or c-MET Abs.

These results are also consistent with those of Castoldi et al. (21) who demonstrated that an EGFR × c-MET BsAb could preclude the c-MET-driven tumor spreading that results from unbalanced EGFR inhibition in the presence of HGF. We corroborate their conclusions by demonstrating a distinct advantage of working with BsAbs, i.e. their intrinsic capacity to achieve balanced inhibition of interactive receptor systems such as EGFR and c-MET.

Affinity, target antigen density, and Ab binding are highly interdependent (2), i.e. the binding of a low affinity Ab will be influenced by avidity to a much greater extent than the binding of a high affinity Ab. Malignant cells frequently express certain antigens at significantly higher levels than normal cells (9–11). Therefore, as long as the affinity of either arm is not too high, a bispecific Ab that binds to at least one overexpressed target on malignant cells frequently expressed certain antigens at significantly higher levels than normal cells (9–11). Therefore, as long as the affinity of either arm is not too high, a bispecific Ab that binds to at least one overexpressed target on a cancer cell should, as a result of dual-receptor avidity, preferentially bind to tumor cells rather than normal cells. This argument suggests how target antigen density and affinity might be used to guide BsAb design. For example, if one of two targeted antigens is significantly overexpressed in tumor versus normal cells, it might be advantageous to have the corresponding arm of the BsAb be of relatively low affinity to minimize its binding to healthy cells. Similarly, when both targeted antigens are overexpressed on the cancer cells, engineering lower affinities into both arms of the BsAb should minimize interactions with healthy cells. In both cases, dual-target avidity would drive preferential accumulation of the BsAb onto the target cells, thus securing both specificity and efficacy.

We confirmed that expression differences can be used to decipher the mechanisms of BsAb target engagement and target occupancy on the surface of cancer cells. The differences of receptor density levels can affect bispecific Ab efficacy. Thus panels of BsAbs, which can be readily generated by cFAE, should be screened using variable pools of parental mAbs to determine empirically the most effective target affinity combinations. The paradigm that cancer cells could be preferentially targeted via dual-target avidity traps with BsAbs of calibrated affinities could be tested in vitro and prototyped in vivo using xenograft models. Such characterizations can be applied to target cells for indications other than cancer.

References
1. Rudnick, S. I., and Adams, G. P. (2009) Affinity and avidity in antibody-based tumor targeting. Cancer Biother. Radiopharm. 24, 155–161.
2. Zuckier, L. S., Berkowitz, E. Z., Sattenberg, R. J., Zhao, Q. H., Deng, H. F., and Scharff, M. D. (2000) Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res. 60, 7008–7013.
3. Derer, S., Bauer, P., Lohse, S., Scheel, A. H., Berger, S., Kellner, C., Peipp, M., and Valerius, T. (2012) Impact of epidermal growth factor receptor (Egfr) cell surface expression levels on effector mechanisms of Egfr antibodies. J. Immunol. 189, 5230–5239.
4. Velders, M. P., van Rhijn, C. M., Oskam, E., Fleuren, G. J., Warnaar, S. O., and Litvinov, S. V. (1998) The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immuno-therapy of carcinomas. Br. J. Cancer 78, 478–483.
5. Lewis, G. D., Figari, I., Fendly, B., Wong, W. L., Carter, P., Gorman, C., and Shepard, H. M. (1993) Differential responses of human tumor cell lines to anti-P185her2 monoclonal antibodies. Cancer Immunol. Immunother. 37, 255–263.
6. Tang, Y., Lou, J., Alpaugh, R. K., Robinson, M. K., Marks, J. D., and Weiner, L. M. (2007) Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J. Immunol. 179, 2815–2823.
7. Laurent, S., Queirolo, P., Boero, S., Salvi, S., Piccioli, P., Boccardo, S., Minigelli, S., Morabito, A., Fontana, V., Pietra, G., Carrega, P., Ferrari, N., Tosetti, F., Chang, L. J., Mingari, M. C., Ferlazzo, G., et al. (2013) The engagement of Cila-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and Tnfr-a production. J. Transl. Med. 11, 109.
8. Beers, S. A., French, R. R., Chan, H. T., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijaya-weera, S. S., Dixon, S. V., Kim, H., Cox, K. L., Kerr, J. P., Johnston, D. A., Johnson, P. W., Verbeek, J. S., Glennie, M. J., and Cragg, M. S. (2010) Antigenic modulation limits the efficacy of anti-Cd20 antibodies: implications for antibody selection. Blood 115, 5191–5201.
9. Drach, J., Drach, D., Glassl, H., Gattringer, C., and Huber, H. (1992) Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 13, 893–901.
10. Farahat, N., Lens, D., Zomas, A., Morilla, R., Matutes, E., and Catovsky, D. (1995) Quantitative flow cytometry can distinguish between normal and leukemic B-cell precursors. Br. J. Haematol. 91, 640–646.
11. Maher, K. J., and Fletcher, M. A. (2005) Quantitative flow cytometry in the clinical laboratory. Clin. Appl. Immunol. Rev. 5, 353–372.
12. Bene, M. C., Castoldi, G., Knapp, W., Ludwig, W. D., Matutes, E., Orfao, A., and van’t Veer, M. B. (1995) Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (Egl). Leukemia 9, 1783–1786.
13. Engelberts, P. J., Badoil, C., Beurkens, F. J., Boulay-Moine, D., Grivel, K., Parren, P. W., and Moulard, M. (2013) A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab. J. Immunol. Methods 388, 8–17.
14. Turner, N. C., and Beis-Filho, J. S. (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 13, e178–e185.
15. Magee, J. A., Piskounova, E., and Morrison, S. J. (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283–296.
16. Janku, F. (2014) Tumor heterogeneity in the clinic: is it a real problem? Ther. Adv. Med. Oncol. 6, 43–51.
17. Bai, H., Wang, Z., Yang, Y., Zhao, M., Zhou, Q., Duan, J., Yang, L., Wu, M., An, T., Zhao, J., and Wang, J. (2013) Detection and clinical significance of intratumoral Egfr mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS ONE 8, e54170.
18. Sequist, L. V., Walthman, B. A., Dias-Santagata, D., Dugumarty, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., Akhavanfard, S., Heist, R. S., Temel, J., Christensen, J. G., Wain, J. C., et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26.
19. Karamouzis, M. V., Konstantinopoulos, P. A., and Papavassiliou, A. G.
Relative Antigen Levels Affect Bispecific Antibody Behavior

(2009) Targeting met as a strategy to overcome crosstalk-related resistance to Egfr inhibitors. *Lancet Oncol.* **10**, 709–717

20. Nguyen, K. S., Kobayashi, S., and Costa, D. B. (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. *Clin. Lung Cancer* **10**, 281–289

21. Castoldi, R., Ecker, V., Wiehle, L., Majety, M., Busl-Schuller, R., Asmussen, M., Nopora, A., Jucknischke, U., Osl, F., Kobold, S., Scheuer, W., Venturi, M., Klein, C., Niederfellner, G., and Sustmann, C. (2013) A novel bispecific Egfr/met antibody blocks tumor-promoting phenotypic effects induced by resistance to Egfr inhibition and has potent antitumor activity. *Oncogene* **32**, 5593–5601

22. Puri, N., and Salgia, R. (2008) Synergism of Egfr and C-met pathways, cross-talk and inhibition, in non-small cell lung cancer. *J. Carcinog.* **7**, 9

23. Bean, J., Brennan, C., Shih, J. Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., Balk, M., Chang, W. C., Yu, C. J., Gazdar, A., Pass, H., et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 20932–20937

24. Labrijn, A. F., Meesters, J. L., de Goey, B. E., van den Bremer, E. T., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., van Berkel, P. H., van de Winkel, J. G., Schuurman, J., and Parren, P. W. (2013) Efficient generation of stable bispecific IgG1 by controlled fab-arm exchange. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 5145–5150

25. Wang, L., Abbasi, F., Gaigalas, A. K., Hoffman, R. A., Flagler, D., and Marti, G. E. (2007) Discrepancy in measuring CD4 expression on T-lymphocytes using fluorescein conjugates in comparison with unimolar CD4-phycoerythrin conjugates. *Cytometry B Clin. Cytom.* **72**, 442–449

26. Pannu, K. K., Joe, E. T., and Iyer, S. B. (2001) Performance evaluation of QuantIBRITE phycoerythrin beads. *Cytometry* **45**, 250–258

27. Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., and Catovsky, D. (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. *J. Clin. Pathol.* **51**, 364–369

28. Iyer, S. B., Hultin, L. E., Zawadzki, J. A., Davis, K. A., and Giorgi, J. V. (1998) Quantitation of CD38 expression using QuantiBRITE beads. *Cytometry* **33**, 206–212

29. Poncelet, P., Poinas, G., Corbeau, P., Devaux, C., Tubiana, N., Muloko, N., Tamalet, C., Chermant, J. K., Kourilsky, F., and Sampol, J. (1991) Surface CD4 density remains constant on lymphocytes of Hiv-infected patients in the progression of disease. *Res. Immunol.* **142**, 291–298

30. Rego, E. M., Garcia, A. B., Carneiro, J. J., and Falcao, R. P. (2001) Immunophenotype of normal and leukemic bone marrow B-precurors in a Brazilian population. A comparative analysis by quantitative fluorescence cytometry. *Braz. J. Med. Biol. Res.* **34**, 183–194

31. Hsi, E. D., Kopecky, K. J., Appelbaum, F. R., Boldt, D., Frey, T., Loftus, M., and Hussein, M. A. (2003) Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukemia. *Br. J. Haematol.* **120**, 1017–1025

32. Farahat, N., Lens, D., Zomas, A., Morilla, R., Matutes, E., and Catovsky, D. (1995) Quantitative flow cytometry can distinguish between normal and leukemic B-cell precursors. *Br. J. Haematol.* **91**, 640–646

33. Io, M., Stolz, D. B., Esplen, J. E., Dorko, K., Michalopoulos, G. K., and Strom, S. C. (2000) Cross-talk between epidermal growth factor receptor and C-met signal pathways in transformed cells. *J. Biol. Chem.* **275**, 8806–8811

34. Ferrand, V. L., Montero Julian, F. A., Chauvet, M. M., Hirn, M. H., and Bourdeau, M. J. (1996) Quantitative determination of the Mrd-related P-glycoprotein, Pgp 170, by a rapid flow cytometric technique. *Cytometry* **23**, 120–125

35. Zenger, V. E., Vogt, R., Mandy, F., Schwartz, A., and Marti, G. E. (1998) Quantitative flow cytometry: inter-laboratory variation. *Cytometry* **33**, 138–145

36. Wang, L., Abbasi, F., Ornatsky, O., Cole, K. D., Misakian, M., Gaigalas, A. K., He, H. J., Marti, G. E., Tanner, S., and Stebbings, R. (2012) Human CD4+ lymphocytes for antigen quantification: characterization using conventional flow cytometry and mass cytometry. *Cytometry B* **81**, 567–575

37. Bikoue, A., George, F., Poncelet, P., Mutin, M., Janossy, G., and Sampol, J. (1996) Quantitative analysis of leukocyte membrane antigen expression: normal adult values. *Cytometry* **26**, 137–147

38. Davis, K. A., Abrams, B., Iyer, S. B., Hoffman, R. A., and Bishop, J. E. (1998) Determination of CD4 antigen density on cells: role of antibody valency, avidity, clones, and conjugation. *Cytometry* **33**, 197–205

39. Panke, C., Weininger, D., Hasa, A., Schelter, F., Schluthauer, T., Bader, S., Sirca, R., Jesel, H. P., Baer, U., Burtscher, H., Mundigl, O., Grote, M., Brinkmann, U., and Sustmann, C. (2013) Quantification of cell-surface proteins with bispecific antibodies. *Protein Eng. Des. Sel.* **26**, 645–654

40. Langley, K. E., Villarejo, M. R., Fowler, A. V., Zamenhof, P. J., and Zabin, I. (1975) Molecular basis of β-galactosidase α-complementation. *Proc. Natl. Acad. Sci. U.S.A.* **72**, 1254–1257

41. Wehrman, T. S., von Degenfeld, G., Krutzik, P. O., Nolan, G. P., and Blau, H. M. (2006) Luminescent imaging of β-galactosidase activity in living subjects using sequential reporter-enzyme luminescence. *Nature Methods* **3**, 295–301

42. Rossmann, E. D., Lenkei, R., Lundin, J., Mellstedt, H., and Osterborg, A. (2007) Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia. *Cytometry B Clin. Cytom.* **72**, 450–457

43. Grata, J. W., D’hautcourt, J. L., Mandy, F., Rothe, G., Barnett, D., Janossy, G., Papa, S., Schmitz, G., and Lenkei, R. (1998) Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European working group on clinical cell analysis. *Cytometry* **33**, 166–178

44. Kornilova, E. S., Taverna, D., Hoeck, W., and Hynes, N. E. (1992) Surface expression of Erbb-2 protein is post-transcriptionally regulated in mammary epithelial cells by epidermal growth factor and by the culture density. *Oncogene* **7**, 511–519